Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Kotecha on MR-Guided Radiotherapy in Lung Cancer

March 23rd 2022

Rupesh Rajesh Kotecha, MD, discusses the use of magnetic resonance–guided radiotherapy in lung cancer.

Adjuvant Pembrolizumab Improves DFS in Stage IB to IIIA NSCLC, Irrespective of PD-L1 Expression

March 18th 2022

Pembrolizumab was found to significantly improve disease-free survival vs placebo when used in the adjuvant treatment of patients with stage IB to IIIA non–small cell lung cancer following surgical resection, meeting 1 of the dual primary end points of the phase 3 KEYNOTE-091 trial.

The Most Important Thing About a Master Plan Is Not Having One: Pasi A. Jänne Is a Giant of Cancer Care in Lung Cancer

March 18th 2022

Pasi A. Jänne, MD, PhD, discovered a new way to treat lung cancer by following his intuition and staying flexible to pursue opportunities as they arise

Dr. Santos on the Utilization of Approved Monotherapies in NSCLC

March 17th 2022

Edgardo S. Santos, MD, FACP, discusses the utilization of approved monotherapies in non–small cell lung cancer.

Dr. Socinski on Treatment Considerations for Difficult-to-Treat Patients in Lung Cancer

March 17th 2022

Mark A. Socinski, MD, executive director, Thoracic Center, medical oncologist, AdventHealth Cancer Institute, discusses therapeutic considerations for difficult-to-treat patients in lung cancer.

FDA Green Lights Companion Diagnostic for EGFR Therapies Targeting Exon 19 Deletions or Exon 21 Alterations in NSCLC

March 17th 2022

The FDA has approved the FoundationOne CDx for use as a companion diagnostic to determine which patients with non–small cell lung cancer whose tumors harbor EGFR exon 19 deletions or exon 21 substitutions may derive benefit from EGFR TKIs that have been greenlit by the agency for this indication.

Toripalimab/Chemo Combo Provides Significant Survival Benefit in NSCLC Without EGFR/ALK Mutations

March 16th 2022

The addition of toripalimab to chemotherapy resulted in improved progression-free survival and overall survival vs chemotherapy alone in patients with treatment-naïve advanced non–small cell lung cancer without EGFR or ALK mutations.

Sugemalimab Shows Efficacy as Consolidation Therapy in Unresectable Stage III NSCLC

March 11th 2022

Sugemalimab significantly prolonged progression-free survival (PFS) vs placebo in Chinese patients with locally advanced, unresectable, stage III non–small cell lung cancer who did not progress after concurrent or sequential chemoradiotherapy.

Frontline Poziotinib Produces Clinically Meaningful Efficacy in NSCLC Harboring HER2 Exon 20 Insertion Mutations

March 7th 2022

Poziotinib elicited encouraging responses when given at a daily dose of 16 mg in the first-line treatment of patients with non–small cell lung cancer with HER2 exon 20 insertion mutations.

FDA Approves Neoadjuvant Nivolumab/Chemo for Resectable NSCLC

March 4th 2022

The FDA has approved nivolumab plus platinum-doublet chemotherapy for adult patients with resectable non–small cell lung cancer in the neoadjuvant setting.

Dr. Iams on the Key Implications of the ADAURA Trial in NSCLC

March 1st 2022

Wade T. Iams, MD, discusses the key implications of the phase 3 ADAURA trial in non–small cell lung cancer.

FDA Grants Priority Review to Neoadjuvant Nivolumab/Chemo for Resectable NSCLC

February 28th 2022

The FDA has granted priority review to a supplemental biologics license application for the combination of nivolumab and chemotherapy in the neoadjuvant treatment of patients with resectable non–small cell lung cancer.

Broad Panel Testing Is the First Step in Tailoring Treatment Throughout Lung Cancer

February 22nd 2022

Jacob Sands, MD, discusses biomarker testing in lung cancer, the utilization of neoadjuvant and frontline immunotherapy, and targeted therapy advances in non–small cell lung cancer.

Dr. Leal on the Utilization of PD-1/PD-L1 Inhibitor Monotherapy in Lung Cancer

February 21st 2022

Ticiana Leal, MD, discusses the utilization of PD-1 and PD-L1 inhibitor monotherapy in lung cancer.

Tepotinib Approved in Europe for METex14-Altered Advanced NSCLC

February 21st 2022

The European Commission has approved tepotinib for use as a single agent in adult patients with advanced non–small cell lung cancer harboring METex14 skipping alterations who require systemic therapy after prior treatment with immunotherapy and/or platinum-based chemotherapy.

SCLC: Future Therapies and Advice to Community Oncologists

February 21st 2022

Drs Carl M. Gay and Jared Weiss highlight several novel strategies that show promise in optimizing treatment for patients with small cell lung cancer and respond to questions from community oncologists who manage treatment for patients with lung cancer.

FDA Approval Sought for Adagrasib in Previously Treated KRAS G12C–Mutated NSCLC

February 15th 2022

The FDA has accepted a new drug application for the use of adagrasib in the treatment of patients with non–small cell lung cancer whose tumors harbor a KRAS G12C mutation and who have previously received at least 1 prior systemic therapy.

FDA Accepts NDA for Poziotinib in HER2 Exon 20–Mutated NSCLC

February 14th 2022

The FDA has accepted for review a new drug application for poziotinib in patients with previously treated locally advanced or metastatic non–small cell lung cancer with HER2 exon 20 insertion mutations.

Future Perspectives in EGFR+ NSCLC

February 14th 2022

Global perspectives on the future management of EGFR+ non–small cell lung cancer given recent advances in the treatment paradigm.

EGFR+ Advanced NSCLC Resistant to Frontline TKIs: C797S Mutation

February 14th 2022

Expert perspectives on the management of C797S-mutated non–small cell lung cancer following failure of frontline TKIs.